Payment overview · 2025
General Payments
$522.10
29 reported records · 20 companies
Healthcare provider profile · identity verified
Julia Degler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREENFIELD, IN · NPI 1295996346
Verified facts
What the public records show
CMS Open Payments records show Julia Degler, M.D. received $522.10 in general payments during 2025 across 29 reported records.
Exact Sciences Corporation accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.77 | 13.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.25 | 9.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.32 | 9.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.50 | 8.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.99 | 7.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.47 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.57 | 4.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.77 | 4.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.44 | 3.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.82 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.16 | 3.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.87 | 3.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.69 | 3.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.50 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.15 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.87 | 3.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.01 | 2.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $13.78 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.74 | 2.6% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $8.43 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $522.10 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.99 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 23 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 68 |
| Omeprazole | Omeprazole | 251 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 49 |
| Losartan Potassium | Losartan Potassium | 211 | 60 |
| Alendronate Sodium | Alendronate Sodium | 205 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 45 |
| Gabapentin | Gabapentin | 139 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 36 |
| Furosemide | Furosemide | 135 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 29 |
| Lisinopril | Lisinopril | 108 | 28 |
| Metformin Hcl Er | Metformin Hcl | 100 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 21 |
| Simvastatin | Simvastatin | 71 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Donepezil Hcl | Donepezil Hcl | 66 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 13 |
| Potassium Chloride | Potassium Chloride | 55 | 16 |
| Cephalexin | Cephalexin | 54 | 30 |
| Metformin Hcl | Metformin Hcl | 52 | 15 |
| Prednisone | Prednisone | 51 | 39 |
| Alprazolam | Alprazolam | 50 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Allopurinol | Allopurinol | 44 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 43 | 11 |
| Carvedilol | Carvedilol | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Myrbetriq | Mirabegron | 40 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 25 |
| Spironolactone | Spironolactone | 38 | 14 |
| Trazodone Hcl | Trazodone Hcl | 37 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Nystatin | Nystatin | 32 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Eliquis | Apixaban | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 23 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $522.10 · 29 records | Exact Sciences Corporation | Auvelity, Azstarys, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, LEQVIO, LINZESS, LOREEV XR, NURTEC ODT, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VYNDAMAX, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error